Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome
Eldad J. Dann(Rambam Health Care Campus), Ron Epelbaum(University of Bern), Menachem Ben‐Shachar(Rambam Health Care Campus), Nissim Haim(Technion – Israel Institute of Technology), Diana Libster, Tzila Zuckerman(Rambam Health Care Campus), Jacob M. Rowe(Technion – Israel Institute of Technology), Mark Kirschbaum(Cyclacel Pharmaceuticals (United States)), Irit Avivi(Tel Aviv Sourasky Medical Center), Rachel Bar‐Shalom(Rambam Health Care Campus), Ada Tamir(Technion – Israel Institute of Technology), Odelia Goor(Tel Aviv Sourasky Medical Center)
Cited by 124
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907